Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMMER: Mepolizumab in COPD
NCT05138250Phase 3Completed
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- May 2022
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of mepolizumab in chronic obstructive pulmonary disease (COPD), sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Started May 2022; status: completed.
02
Drugs
mepolizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05138250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05138250.